Abstract
Objective
The antidiabetic drug metformin has been associated in a small number of patients with lactic acidosis, a serious condition with a poor prognosis. However, because of lack of data, the prognostic significance of hyperlactataemia in metformin-treated patients is not known.
Methods
Data were collected from 49 metformin-treated patients with lactic acidosis (arterial lactate level ≥5 mmol/L and blood pH ≤7.35) and available plasma metformin concentration data to investigate the association of arterial lactate levels and plasma metformin concentrations with mortality.
Results
The overall mortality rate in this patient sample was 45% and the median arterial lactate level was 13.1 mmol/L. Median lactate levels were similar in patients who survived (13 mmol/L) and those who died (14.3 mmol/L), whereas the median plasma metformin concentration was 3 times higher in patients who survived (20.6 mg/L versus 6.3 mg/L).
Conclusion
In this, the largest series of metformin-treated patients with lactic acidosis yet reported, 55% of patients survived and these patients had a median arterial lactate level of 13.1 mmol/L. Neither arterial lactate levels nor plasma metformin concentrations were of prognostic significance in relation to mortality in this sample of metformin-treated patients with lactic acidosis. Death in these patients appeared instead to be associated with other hypoxic disease or underlying ill health. These observations suggest that accumulation of metformin may not be as significant with respect to high arterial levels of lactate and their effects as has been traditionally thought.
Similar content being viewed by others
References
Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994; 11: 223–41
Perets D, Scott H, Duff J, et al. The significance of lactic acidosis in the shock syndromes. Ann N Y Acad Sci 1965; 119: 1133–41
Cady Jr LD, Weil MH, Afifi AA, et al. Quantitation of severity of critical illness with special reference to blood lactate. Crit Care Med 1973; 1: 75–80
Stacpoole PW, Wright EC, Baumgartener TG, et al. Natural history and course of acquired lactic acidosis in adults. DCA-Lactic Acidosis Study Group. Am J Med 1994; 97: 47–54
Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574–9
Assan R, Heuclin C, Ganeval D, et al. Metformin-induced lactic acidosis in the presence of acute renal failure. Diabetologia 1977; 13: 211–7
Sirtori CR, Pasik C. Re-evaluation of a biguanide, metformin: mechanism of action and tolerability. Pharmacol Res 1994; 30: 187–228
Lalau JD, Lacroix C, Compagnon P, et al. Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care 1995; 18: 779–84
Lacroix C, Danger P, Wojciechowski F. Microdosage de la metformine plasmatique et intra-érythrocytaire par Chromatographie en phase liquide. Ann Biol Clin (Paris) 1991; 49: 98–101
Stacpoole PW. Lactic acidosis. Endocrinol Metab Clin North Am 1993; 22: 221–45
Fulop M, Hoberman HD. Phenformin-associated metabolic acidosis. Diabetes 1976; 25: 292–6
Nattrass M, Todd PG, Hinks L, et al. Comparative effects of phenformin, metformin and glibenclamide in metabolic rhythms in maturity-onset diabetes. Diabetologia 1977; 13: 145–52
Jackson RA, Hawa MI, Jaspan JV, et al. Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes 1987; 36: 632–40
Oates NS, Shah RR, Idle JR, et al. Genetic polymorphism of phenformin 4-hydroxylation. Clin Pharmacol Ther 1982; 32: 81–9
Cusi K, Consoli A, De Fronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulindependent diabetes mellitus. J Clin Endocrinol Metab 1996; 81: 4059–67
Bailey CJ, Wilcock C, Day C. Effect of metformin on glucose metabolism in the splanchnic bed. Br J Pharmacol 1992; 105: 1009–13
Bailey CJ. Metformin — an update. Gen Pharmacol 1993; 24: 1299–309
Cohen RD, Woods HF. Clinical and biochemical aspects of lactic acidosis. Oxford: Blackwell Scientific, 1976
Montanari G, Bondioli A, Rizzato G, et al. Treatment with low dose metformin in patients with peripheral vascular disease. Pharmacol Res 1992; 25: 63–73
Sirtori CR, Franceschini G, Gianfranceschi G, et al. Metformin improves peripheral vascular flow in nonhyperlipidemic patients with arterial disease. J Cardiovasc Pharmacol 1984; 6: 914–23
Bouskela E, Wiernsperger N. Effects of metformin on hemorrhagic shock, blood volume, and ischemia/reperfusion on nondiabetic hamsters. J Vasc Med Biol 1993; 4: 41–6
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lalau, JD., Race, JM. Lactic Acidosis in Metformin-Treated Patients. Drug-Safety 20, 377–384 (1999). https://doi.org/10.2165/00002018-199920040-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199920040-00006